The takeaway
A pooled analysis found no meaningful average worsening of depression symptoms with tirzepatide versus placebo. That does not establish safety for every mental-health situation.
Who took part?
Researchers revisited three SURMOUNT trials involving 4,056 adults with overweight or obesity. Participants received weekly tirzepatide or placebo for 72 weeks, alongside lifestyle support.
People with certain serious psychiatric conditions, significant depression symptoms, or a history of suicide attempt were excluded. Average depression symptoms were minimal at the start.
Themes from a selected population; not a depression-treatment trial
At the start
Average depression symptoms were minimal
Over 72 weeks
No clinically meaningful average difference
Rare events
Too few to establish cause
Original visual based on the study.
| Group or measure | Result |
|---|---|
| At the start | Average depression symptoms were minimal |
| Over 72 weeks | No clinically meaningful average difference |
| Rare events | Too few to establish cause |
What changed?
Depression questionnaire scores remained low in both groups. A small difference favored tirzepatide, but the authors did not consider it clinically meaningful. This was not a trial of depression treatment.
Suicidal thoughts were reported by 0.6% in each group. Two tirzepatide participants reported nonfatal suicidal behavior, compared with none receiving placebo. The numbers were too small to determine whether this difference reflected treatment or chance.
What remains uncertain?
This was a post-hoc analysis without adjustment for multiple comparisons. Findings cannot simply be extended to people excluded from the trials.
Eli Lilly funded the analysis.